ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

NDAQ:ACAD - Post by User

ACADIA Pharmaceuticals Inc

Bullboard Posts

Comment by vforvalueon Jun 20, 2008 11:46am

1911 Views

Post# 15209264

RE: Long Term Hold?

For long term, i would def. consider this stock a buy!
Like you mentioned, the baby boom era def. benefits this company
I also like that ACAD is advancing its two major products aggressively! There is no time to waste here!
They have several new lines in the making with little debt
Unlike other bio companies, ACADIA is already making revenue and has 100% gross margin!
This company is conservative with its expenses as you can see that there is only 143 employees working!
With positive news, this company could get a hit!
I will def. keep an eye out for it!

Bullboard Posts

Global Tungsten Market and Supply Security